Vistagen Therapeutics Inc (VTGN) Unusual Options Activity Today

Checking VTGN unusual options activity helps you spot when traders are making outsized bets on Vistagen Therapeutics Inc before the broader market catches on. Vistagen Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor VTGN unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching VTGN unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking VTGN unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and VTGN unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders.

The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Catalysts rarely arrive without a footprint, and VTGN unusual options activity is often where that footprint shows up first. Our scanner tracks Vistagen Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at VTGN unusual options volume on the call side or chasing put sweeps, Vistagen Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.